Clarient Reports First Quarter 2008(r the development of novel diagnostic te...),Health

Date:4/30/2008

r the development of novel diagnostic tests, whether the conditions to payment of all or any portion of the contingent consideration from the Company's sale of its instrument systems business to Zeiss are satisfied, the Company's ability to remediate the material weaknesses in the Company's internal control over financial reporting, the Company's ability to successfully transition its customer billings from a third party billing vendor to an in-house billing system, the continuation of favorable third party payer reimbursement for laboratory tests, the Company's ability to obtain additional financing on acceptable terms or at all, unanticipated expenses or liabilities or other adverse events affecting cash flow, uncertainty of success in identifying and developing new diagnostic tests or novel markers, the Company's ability to fund development of new diagnostic tests and novel markers and the amount of resources the Company determines to apply to novel marker development and commercialization, the Company's ability to obtain additional financing if required on favorable terms or at all, failure to obtain FDA clearance or approval for particular applications, the Company's ability to compete with other technologies and with emerging competitors in novel cancer diagnostics and dependence on third parties for collaboration in developing new tests, and risks detailed from time to time in the Company's SEC reports, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. Recent experience with respect to laboratory services, revenues and results of operations may not be indicative of future results for the reasons set forth above. In addition, the financial results described herein are preliminary and subject to adjustment as the Company finalizes its review of its financial results for the quarter ended March 31, 2008. The Company's financial statements for the quarter ended March 31, 2008 (including any such adjustments, if any) wi
'/>"/>

SOURCE Clarient, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine news :

1. Clarient to Present at the B. Riley & Co. 9th Annual Las Vegas Investor Conference
2. Clarient CEO Andrews to Participate in Panel Discussion at the RBC Capital Markets 2007 Healthcare Conference
3. Clarient Named to Deloittes 2007 Orange County Technology Fast 50 for Third Consecutive Year
4. Clarient Generates 52% Revenue Increase in Third Quarter 2007
5. Clarient Names Michele Hibbard, Ph.D. Director of Genetics
6. Clarient Names Michael J. Pellini, M.D. Chief Operating Officer
7. Clarient to Present at the UBS 2007 Global Life Sciences Conference
8. J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers
9. Garmin Reports Record First Quarter; Strong Margins and Increased Market Share
10. ViroPharma Incorporated Reports First Quarter 2008 Financial Results
11. Columbia River Resources Inc subsidiary, Traxxec Ltd, reports coverage of its technology at Interpack 2008 (Pink Sheets OTC - CRVR.pk)